128.07
price up icon0.70%   0.89
after-market Handel nachbörslich: 127.75 -0.32 -0.25%
loading
Schlusskurs vom Vortag:
$127.18
Offen:
$127.09
24-Stunden-Volumen:
6.76M
Relative Volume:
0.98
Marktkapitalisierung:
$158.91B
Einnahmen:
$29.05B
Nettoeinkommen (Verlust:
$8.11B
KGV:
19.84
EPS:
6.4563
Netto-Cashflow:
$9.16B
1W Leistung:
+3.78%
1M Leistung:
+4.28%
6M Leistung:
+20.64%
1J Leistung:
+45.95%
1-Tages-Spanne:
Value
$125.86
$128.10
1-Wochen-Bereich:
Value
$122.50
$128.10
52-Wochen-Spanne:
Value
$87.77
$128.10

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Firmenname
Gilead Sciences Inc
Name
Telefon
(650) 574-3000
Name
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Name
Mitarbeiter
17,600
Name
Twitter
@GileadSciences
Name
Nächster Verdiensttermin
2025-02-11
Name
Neueste SEC-Einreichungen
Name
GILD's Discussions on Twitter

Vergleichen Sie GILD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
128.07 157.79B 29.05B 8.11B 9.16B 6.4563
Drug Manufacturers - General icon
LLY
Lilly Eli Co
1,049.60 921.91B 59.42B 18.41B 6.44B 20.22
Drug Manufacturers - General icon
JNJ
Johnson Johnson
202.51 481.86B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
232.91 413.34B 59.64B 2.36B 19.68B 1.3253
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
127.31 245.62B 54.45B 14.42B 17.15B 7.333
Drug Manufacturers - General icon
MRK
Merck Co Inc
95.05 239.34B 63.90B 19.05B 13.05B 7.5596

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-11-13 Eingeleitet Scotiabank Sector Outperform
2025-08-19 Hochstufung Daiwa Securities Neutral → Outperform
2025-08-08 Hochstufung Truist Hold → Buy
2025-07-25 Hochstufung Needham Hold → Buy
2025-04-22 Fortgesetzt Cantor Fitzgerald Overweight
2025-03-04 Bestätigt Oppenheimer Outperform
2025-02-18 Hochstufung Deutsche Bank Hold → Buy
2025-02-13 Hochstufung DZ Bank Hold → Buy
2025-01-10 Hochstufung Morgan Stanley Equal-Weight → Overweight
2024-12-10 Fortgesetzt BofA Securities Buy
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-11-14 Eingeleitet Citigroup Buy
2024-11-08 Herabstufung Maxim Group Buy → Hold
2024-10-21 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-17 Eingeleitet Bernstein Outperform
2024-10-07 Hochstufung Wells Fargo Equal Weight → Overweight
2024-07-08 Hochstufung Raymond James Mkt Perform → Outperform
2024-05-01 Bestätigt Maxim Group Buy
2024-04-24 Hochstufung HSBC Securities Reduce → Hold
2024-02-22 Herabstufung Truist Buy → Hold
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-09-08 Hochstufung BofA Securities Neutral → Buy
2023-09-06 Eingeleitet HSBC Securities Reduce
2023-07-24 Bestätigt Barclays Equal Weight
2023-05-16 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-04-28 Fortgesetzt Piper Sandler Overweight
2023-01-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Fortgesetzt BofA Securities Neutral
2022-12-09 Herabstufung DZ Bank Buy → Hold
2022-10-31 Hochstufung Barclays Underweight → Equal Weight
2022-10-28 Bestätigt BMO Capital Markets Market Perform
2022-10-28 Bestätigt Cowen Outperform
2022-10-28 Bestätigt JP Morgan Overweight
2022-10-28 Bestätigt Jefferies Buy
2022-10-28 Hochstufung Piper Sandler Neutral → Overweight
2022-10-28 Bestätigt RBC Capital Mkts Outperform
2022-10-28 Hochstufung Truist Hold → Buy
2022-10-28 Bestätigt Wells Fargo Equal Weight
2022-10-04 Hochstufung JP Morgan Neutral → Overweight
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-05-23 Eingeleitet SVB Leerink Mkt Perform
2022-02-28 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-02-02 Bestätigt BMO Capital Markets Outperform
2022-02-02 Bestätigt BofA Securities Neutral
2022-02-02 Bestätigt RBC Capital Mkts Outperform
2022-02-02 Bestätigt Truist Hold
2022-02-02 Bestätigt Wells Fargo Equal Weight
2022-01-28 Hochstufung Argus Hold → Buy
2022-01-06 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-12-06 Eingeleitet Goldman Neutral
2021-11-19 Hochstufung BMO Capital Markets Market Perform → Outperform
2021-11-19 Fortgesetzt Piper Sandler Neutral
2021-10-20 Fortgesetzt Cowen Outperform
2021-07-30 Bestätigt BMO Capital Markets Market Perform
2021-07-30 Bestätigt RBC Capital Mkts Outperform
2021-04-01 Hochstufung Bernstein Mkt Perform → Outperform
2021-03-30 Hochstufung Redburn Neutral → Buy
2021-01-19 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-01-04 Hochstufung Guggenheim Neutral → Buy
2020-11-03 Fortgesetzt Morgan Stanley Equal-Weight
2020-10-28 Eingeleitet UBS Neutral
2020-09-30 Fortgesetzt Jefferies Buy
2020-09-15 Hochstufung Maxim Group Hold → Buy
2020-07-31 Bestätigt Credit Suisse Neutral
2020-07-31 Bestätigt Morgan Stanley Equal-Weight
2020-07-31 Bestätigt Piper Sandler Overweight
2020-07-31 Bestätigt RBC Capital Mkts Outperform
2020-07-31 Bestätigt SunTrust Hold
2020-07-31 Bestätigt Wells Fargo Equal Weight
2020-07-20 Hochstufung Credit Suisse Underperform → Neutral
2020-06-03 Hochstufung SVB Leerink Mkt Perform → Outperform
2020-05-26 Hochstufung SunTrust Sell → Hold
2020-05-01 Herabstufung JP Morgan Overweight → Neutral
2020-05-01 Herabstufung Raymond James Outperform → Mkt Perform
2020-05-01 Herabstufung SunTrust Hold → Sell
2020-04-27 Herabstufung UBS Buy → Neutral
2020-04-20 Herabstufung BMO Capital Markets Outperform → Market Perform
2020-04-20 Herabstufung Wells Fargo Overweight → Equal Weight
2020-04-17 Herabstufung CFRA Hold → Sell
Alle ansehen

Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten

pulisher
Nov 19, 2025

Gilead Sciences (GILD): Taking Stock of Valuation as Shares Approach Analyst Targets - Yahoo Finance

Nov 19, 2025
pulisher
Nov 19, 2025

Johanna Mercier Sells 28,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat

Nov 19, 2025
pulisher
Nov 19, 2025

Andrew Dickinson Sells 2,500 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat

Nov 19, 2025
pulisher
Nov 19, 2025

Is Gilead Sciences Inc. (GIS) stock dividend growth reliableVolume Spike & Daily Market Momentum Tracking - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Gilead Sciences' GC Will Leave Co. Next Month - Law360

Nov 19, 2025
pulisher
Nov 19, 2025

Merck’s Two-Drug HIV Regimen Matches Gilead’s Three-Drug TabletMerck & Co (NYSE:MRK) - Benzinga

Nov 19, 2025
pulisher
Nov 19, 2025

Without Explanation, Gilead Sciences Parts Ways With GC It Wooed Aboard in 2022 - Law.com

Nov 19, 2025
pulisher
Nov 19, 2025

Merck's oral HIV treatment non-inferior to Gilead's Biktarvy in late-stage trial - Reuters

Nov 19, 2025
pulisher
Nov 19, 2025

Gilead Sciences (GILD) Announces Executive Leadership Change - GuruFocus

Nov 19, 2025
pulisher
Nov 19, 2025

Gilead at Jefferies London: Strategic Growth and Innovation - Investing.com India

Nov 19, 2025
pulisher
Nov 19, 2025

Gilead Sciences (GILD): Assessing Valuation After Strong Shareholder Returns and Product Pipeline Developments - simplywall.st

Nov 19, 2025
pulisher
Nov 19, 2025

Gilead Sciences announces departure of executive vice president and general counsel - Investing.com

Nov 19, 2025
pulisher
Nov 19, 2025

Gilead Sciences Announces Executive Vice President Departure - TipRanks

Nov 19, 2025
pulisher
Nov 19, 2025

WBI Investments LLC Has $1.66 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 19, 2025
pulisher
Nov 19, 2025

Gilead says Deborah Telman to step down as evp at Gilead SciencesSEC filing - MarketScreener

Nov 19, 2025
pulisher
Nov 19, 2025

Gilead Sciences announces executive departure in December - StreetInsider

Nov 19, 2025
pulisher
Nov 19, 2025

Vanguard Group Inc. Boosts Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 19, 2025
pulisher
Nov 19, 2025

Westover Capital Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 19, 2025
pulisher
Nov 19, 2025

Gilead reports Trodelvy breast cancer trial missed primary survival endpoint - PMLiVE

Nov 19, 2025
pulisher
Nov 19, 2025

'Gilead wants us to rebuild': Why Galapagos isn't allowed to go extinct after turbulent year - Fierce Biotech

Nov 19, 2025
pulisher
Nov 19, 2025

Merck HIV pill matches Gilead’s Biktarvy in trial (MRK:NYSE) - Seeking Alpha

Nov 19, 2025
pulisher
Nov 19, 2025

Invenio Wealth Partners LLC Buys Shares of 3,333 Gilead Sciences, Inc. $GILD - MarketBeat

Nov 19, 2025
pulisher
Nov 19, 2025

SG Americas Securities LLC Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 19, 2025
pulisher
Nov 19, 2025

Gilead Sciences: A Study in Corporate Contrasts - Ad-hoc-news.de

Nov 19, 2025
pulisher
Nov 19, 2025

Why Gilead Sciences Inc. (GIS) stock is a strong analyst pickJuly 2025 Institutional & Safe Investment Capital Preservation Plans - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Gilead Sciences Insider Sold Shares Worth $3,524,173, According to a Recent SEC Filing - MarketScreener

Nov 19, 2025
pulisher
Nov 19, 2025

Can Gilead Sciences Inc. stock beat market expectations this quarterWeekly Investment Summary & AI Optimized Trade Strategies - newser.com

Nov 19, 2025
pulisher
Nov 18, 2025

Insider Sell: Andrew Dickinson Sells Shares of Gilead Sciences I - GuruFocus

Nov 18, 2025
pulisher
Nov 18, 2025

Gilead joins partners for delivery of first shipments of breakthrough twice-yearly lenacapavir for HIV prevention to sub-Saharan Africa - European AIDS Treatment Group

Nov 18, 2025
pulisher
Nov 18, 2025

Gilead Sciences’ (GILD) chief commercial officer sells $3.5m in stock - Investing.com UK

Nov 18, 2025
pulisher
Nov 18, 2025

Raiffeisen Bank International AG Trims Position in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 18, 2025
pulisher
Nov 18, 2025

Nomura Asset Management Co. Ltd. Trims Stake in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 18, 2025
pulisher
Nov 18, 2025

First doses of HIV prevention drug lenacapavir delivered to Zambia, Eswatini - Reuters

Nov 18, 2025
pulisher
Nov 18, 2025

Gilead Sciences, Inc. $GILD is LSV Asset Management's 9th Largest Position - MarketBeat

Nov 18, 2025
pulisher
Nov 18, 2025

Thoroughbred Financial Services LLC Has $1.10 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 18, 2025
pulisher
Nov 18, 2025

Gilead Sciences, Inc. $GILD Shares Sold by Ontario Teachers Pension Plan Board - MarketBeat

Nov 18, 2025
pulisher
Nov 18, 2025

Gilead Sciences, Inc. $GILD Position Boosted by Citizens Financial Group Inc. RI - MarketBeat

Nov 18, 2025
pulisher
Nov 18, 2025

Gilead (GILD) Begins Shipments of HIV Prevention Drug to Africa - GuruFocus

Nov 18, 2025
pulisher
Nov 18, 2025

Gilead ships first lenacapavir doses to sub-Saharan Africa - StreetInsider

Nov 18, 2025
pulisher
Nov 18, 2025

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa - Business Wire

Nov 18, 2025
pulisher
Nov 18, 2025

Cetera Investment Advisers Purchases 21,966 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Nov 18, 2025
pulisher
Nov 18, 2025

Gilead single tablet regimen of Bictegravir, Lenacapavir for HIV-1 meets primary endpoint in Phase 3... - Medical Dialogues

Nov 18, 2025
pulisher
Nov 18, 2025

Before GLP-1s, a Great Pricing Battle Played Out in Hep C Market - BioSpace

Nov 18, 2025
pulisher
Nov 17, 2025

Is It Too Late to Reassess Gilead After Recent Drug Trial Success? - simplywall.st

Nov 17, 2025
pulisher
Nov 17, 2025

Will Gilead Sciences Inc. stock deliver long term returnsJuly 2025 Patterns & Verified Chart Pattern Trade Signals - newser.com

Nov 17, 2025
pulisher
Nov 17, 2025

Gilead Sciences's Options: A Look at What the Big Money is Thinking - Benzinga

Nov 17, 2025
pulisher
Nov 17, 2025

Universal Beteiligungs und Servicegesellschaft mbH Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 17, 2025
pulisher
Nov 17, 2025

Gilead Sciences, Inc. $GILD Stake Raised by Westpac Banking Corp - MarketBeat

Nov 17, 2025
pulisher
Nov 17, 2025

Letko Brosseau & Associates Inc. Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 17, 2025
pulisher
Nov 17, 2025

Persistent Asset Partners Ltd Invests $767,000 in Gilead Sciences, Inc. $GILD - MarketBeat

Nov 17, 2025
pulisher
Nov 17, 2025

Foundations Investment Advisors LLC Buys 17,318 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Nov 17, 2025

Finanzdaten der Gilead Sciences Inc-Aktie (GILD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general NVO
$49.00
price up icon 3.05%
drug_manufacturers_general PFE
$24.88
price down icon 2.24%
$342.40
price down icon 0.46%
drug_manufacturers_general SNY
$49.55
price down icon 2.19%
drug_manufacturers_general MRK
$95.05
price down icon 1.43%
Kapitalisierung:     |  Volumen (24h):